JCO Journals are now on BlueSky! Give us a follow. @jco-asco.bsky.social @pamelakunzmd.bsky.social @ethicsdoctorp.bsky.social @hemoncwarner.bsky.social @kvanloonmd.bsky.social

Might Google Scholar be headed to the Google Graveyard? hannahshelley.neocities.org/blog/2025_08...

A pleasure and an honor to join @fumikochino.bsky.social & Dr. Ethan Ludmir in this @ascocancer.bsky.social conversation on incomplete reporting and toxicity- minimizing language in oncology! 💗

I don't agree with their peer review model, but the premise here is correct. There are rules of indexing and citation counting that are keeping journals from transforming into modern publication systems.

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers insights.citeline.com/pink-sheet/a...

May the odds be ever in your favor. 4% payline at the NCI. www.cancer.gov/grants-train...

In an unprecedented move, the NIH will soon disinvite dozens of scientists who were about to take positions on advisory councils that make final decisions on grant applications for the US agency, Nature has learnt. go.nature.com/3TEw7GN

Agree. At least a decade of pushing our kids to STEM only. Result: few can critically read or write, entry level computer science/coding jobs were the 1st to get cut with AI, decrease in kids wanting to be physicians.

Yep. Prestige costs money to create (literally: highly-selective journals are more expensive to run in part because of their selectivity, not to mention their staff). And, if gold OA is to be the model, then author or their funders are agreeing to pay per paper for that prestige.

We have life saving cancer drugs and life threatening shortages. See our new op ed with potential solutions in @jco-asco.bsky.social @lymphomadoc.bsky.social @ascocancer.bsky.social ascopubs.org/doi/10.1200/...

There's also a helpful criticism here that, if we have to constantly and meticulously double check the work of AI then is it a tool that really saves us time and effort? And, given that cost/benefit ratio, what are the actual use cases that make using it worthwhile?

‼️ #ASCO25 simultaneous publication by Jacobs et al:  BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation. Read the full article: ascopubs.org/doi/10.1200/...

For breaking news and expert analysis during #ASCO25, turn to #ASCODailyNews! During and after the Meeting, ASCO Daily News has coverage of all the practice-changing research being presented. Bookmark us now: dailynews.ascopubs.org/meetings/asc... #oncsky

The @ascocancer.bsky.social Ed Book is the highest-quality, peer-reviewed, FREE #oncology #MedEd ever. Whether or not you’re at #ASCO25, don’t miss this resource, #OncSky #MedSky, #MedStudentSky! Drop a 📌 in the comments to bookmark the link for later. ascopubs.org/toc/edbk/cur... #OncoAlert

Don't miss it! #ASCODailyNews has your exclusive advanced coverage of important abstracts being presented at #ASCOAM dailynews.ascopubs.org/meetings/asc...

Just announced: ASCO and Google Cloud launch the ASCO Guidelines Assistant, an AI tool for fast access to ASCO's trusted and expert-developed clinical cancer guidelines. Read more in @statnews.com

Exciting news! Making ASCO expert, evidence-based treatment guidelines easier than ever to access.

The first of many simultaneous publications out today in #JCOGO. More to come! #ASCO25

Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

Excellent review article by @bldcancerdoc.bsky.social Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring | JCO Oncology Practice ascopubs.org/doi/10.1200/... @acochran12733.bsky.social @oncoalert.bsky.social

Humanizing Oncology Care: A Strategic Imperative | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/... @acochran12733.bsky.social @ascocancer.bsky.social

Educational Video as an Alternative to Pretest In-Person Genetic Counseling in Candidates for Cancer Genetic Testing: A Randomized Controlled Noninferiority Trial | JCO Oncology Practice ascopubs.org/doi/10.1200/... @acochran12733.bsky.social @ascocancer.bsky.social

Disparities in Endometrial Cancer Mortality: Will Increasing Use of Targeted Therapies Widen the Gap? | JCO Oncology Practice ascopubs.org/doi/pdf/10.1... @ascocancer.bsky.social @acochran12733.bsky.social

Patterns of Homologous Repair Deficiency and BRCA1/2 Testing of Ovarian and Breast Cancers: A Real-World Study of Patients in Community Health Settings in the United States ascopubs.org/doi/10.1200/... #JCOOA #OpenAccess

ICYMI: System-Level Transformations to Increase Patient Participation in Clinical Trials ascopubs.org/doi/10.1200/... #JCOOP

Cancer Patient Perspectives on Clinical Trial Discussion and Informed Consent Through Telemedicine ascopubs.org/doi/10.1200/... #JCOOP

Novel Computational Pipeline Enables Reliable Diagnosis of Inverted Urothelial Papilloma and Distinguishes It From Urothelial Carcinoma ascopubs.org/doi/10.1200/... #JCOCCI #JCOJournals

“In patients with mRCC, Medicare was associated with significantly better survival outcomes compared with Medicaid/no insurance and having secondary insurance was associated with better PFS compared with primary insurance alone.” ascopubs.org/doi/10.1200/... #JCOOA

Generalized Evolutionary Classifier for Evolutionary Guided Precision Medicine ascopubs.org/doi/10.1200/... #JCOPO #OpenAccess

New in #JCOGO: Medical Students' Roadmap to 2030: Bridging the Divide in Global Cancer Care ascopubs.org/doi/10.1200/...

Opportunities for Artificial Intelligence in Oncology: From the Lens of Clinicians and Patients ascopubs.org/doi/10.1200/... #JCOOP #AI

From #JCOOP: “Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications.” ascopubs.org/doi/10.1200/...

Ensuring Representation: A Scoping Review of Interventions to Increase Minority Participation in Cancer-Related Research ascopubs.org/doi/10.1200/... #JCOOP #JCOJournals

Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? ascopubs.org/doi/10.1200/... #JCO #Editorial

ascopubs.org/doi/pdf/10.1... Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights @ascocancer.bsky.social @acochran12733.bsky.social

#JCOOA: Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid ascopubs.org/doi/10.1200/... #OpenAccess

Random forest models ID’d SUVmax as a 🗝️ predictor of recurrence, revealing a nonlinear relationship with sharply ⬆️ risk between SUVmax values of 2-5. Random survival forest analysis ranked SUVmax as the most important feature for predicting recurrence-free survival. ascopubs.org/doi/10.1200/...

Out today in #JCOGO: Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country ascopubs.org/doi/10.1200/... #OpenAccess

Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights ascopubs.org/doi/10.1200/... #JCOOP

New #editorial from #JCOOP: Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice? ascopubs.org/doi/10.1200/...

New from #JCO: Management of Patients With EGFR Exon 20–Mutant Advanced Non–Small Cell Lung Cancer ascopubs.org/doi/10.1200/...

Out now in #JCO: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) ascopubs.org/doi/10.1200/...

New in #JCO: Data, Models, and Visuals: How Data Science Methods Can Augment (Geriatric) Oncology Research ascopubs.org/doi/10.1200/...

Exciting news! The JCO Journals LinkedIn page is now live! Your dedicated hub for the latest breakthroughs, expert insights, and practical guidance from all six ASCO journals. Follow now for real-time updates and invaluable resources: brnw.ch/21wQXN7

New in #GlobalOncology Somatic Landscape of Oncogenic Variants Across the Main Cancer Subtypes in Latin America: A Narrative Review ascopubs.org/doi/10.1200/... #JCOGO #OpenAccess

Prevalence and Associated Factors for Depression Among Patients With Sarcoma ascopubs.org/doi/10.1200/... #JCOOP @ethicsdoctorp.bsky.social @jameabraham.bsky.social

Perceptions and Use of Germline Genetic Testing Among Patients With Prostate Cancer ascopubs.org/doi/10.1200/... #JCOOP #JCOJournals @ethicsdoctorp.bsky.social @jameabraham.bsky.social

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study ascopubs.org/doi/10.1200/... #JCO #OpenAccess